JPWO2019140236A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019140236A5 JPWO2019140236A5 JP2020538629A JP2020538629A JPWO2019140236A5 JP WO2019140236 A5 JPWO2019140236 A5 JP WO2019140236A5 JP 2020538629 A JP2020538629 A JP 2020538629A JP 2020538629 A JP2020538629 A JP 2020538629A JP WO2019140236 A5 JPWO2019140236 A5 JP WO2019140236A5
- Authority
- JP
- Japan
- Prior art keywords
- antisense oligonucleotide
- nucleotide
- sequence
- nucleotide analogs
- dna units
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003729 nucleotide group Chemical group 0.000 claims 46
- 229920000272 Oligonucleotide Polymers 0.000 claims 40
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 38
- 239000000074 antisense oligonucleotide Substances 0.000 claims 38
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 30
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 14
- 239000002773 nucleotide Substances 0.000 claims 13
- 102100018522 SNCA Human genes 0.000 claims 10
- 101710019466 SNCA Proteins 0.000 claims 10
- 210000004027 cells Anatomy 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 150000007523 nucleic acids Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000002777 nucleoside Substances 0.000 claims 5
- -1 Hexitol Nucleic Acid Chemical class 0.000 claims 4
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 3
- 235000000346 sugar Nutrition 0.000 claims 3
- 108020004999 Messenger RNA Proteins 0.000 claims 2
- 206010061536 Parkinson's disease Diseases 0.000 claims 2
- 102000019355 Synucleins Human genes 0.000 claims 2
- 108050006783 Synucleins Proteins 0.000 claims 2
- 230000000875 corresponding Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 229920002106 messenger RNA Polymers 0.000 claims 2
- 125000003835 nucleoside group Chemical group 0.000 claims 2
- 229920000023 polynucleotide Polymers 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-Methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 241000083551 Ena Species 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000001089 Multiple System Atrophy Diseases 0.000 claims 1
- 102000006382 Ribonucleases Human genes 0.000 claims 1
- 108010083644 Ribonucleases Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 102000003802 alpha-Synuclein Human genes 0.000 claims 1
- 108090000185 alpha-Synuclein Proteins 0.000 claims 1
- 230000003042 antagnostic Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000000692 anti-sense Effects 0.000 claims 1
- 230000000295 complement Effects 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000004665 fatty acids Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 230000001483 mobilizing Effects 0.000 claims 1
- 210000003867 nerve cell Anatomy 0.000 claims 1
- 210000002569 neurons Anatomy 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862616994P | 2018-01-12 | 2018-01-12 | |
| US62/616,994 | 2018-01-12 | ||
| PCT/US2019/013255 WO2019140236A1 (en) | 2018-01-12 | 2019-01-11 | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021510511A JP2021510511A (ja) | 2021-04-30 |
| JPWO2019140236A5 true JPWO2019140236A5 (ru) | 2022-01-19 |
Family
ID=65269098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538629A Pending JP2021510511A (ja) | 2018-01-12 | 2019-01-11 | アルファ−シヌクレインを標的とするアンチセンスオリゴヌクレオチドおよびその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200362347A1 (ru) |
| EP (1) | EP3737761A1 (ru) |
| JP (1) | JP2021510511A (ru) |
| KR (1) | KR20200140240A (ru) |
| CN (1) | CN111819283A (ru) |
| AU (1) | AU2019208011A1 (ru) |
| BR (1) | BR112020014011A2 (ru) |
| CA (1) | CA3087966A1 (ru) |
| CO (1) | CO2020009715A2 (ru) |
| EA (1) | EA202091693A1 (ru) |
| IL (1) | IL275903A (ru) |
| MX (1) | MX2020007439A (ru) |
| PE (1) | PE20211749A1 (ru) |
| SG (1) | SG11202006528XA (ru) |
| WO (1) | WO2019140236A1 (ru) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201991720A1 (ru) | 2017-02-17 | 2020-01-20 | Бристол-Маерс Сквибб Компани | Антитела к альфа-синуклеину и их применения |
| TWI809004B (zh) | 2017-11-09 | 2023-07-21 | 美商Ionis製藥公司 | 用於降低snca表現之化合物及方法 |
| WO2019140231A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
| CA3090901A1 (en) | 2018-02-12 | 2019-08-15 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
| AU2021206182A1 (en) * | 2020-01-06 | 2022-07-28 | AUM LifeTech, Inc. | Antisense oligonucleotides for treatment of neurological disorders |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| DE69233046T2 (de) | 1991-10-24 | 2004-03-04 | Isis Pharmaceuticals, Inc., Carlsfeld | Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| EP1557424A1 (en) | 1997-09-12 | 2005-07-27 | Exiqon A/S | Bi-cyclic nucleoside, nucleotide and oligonucleoide analogues |
| BRPI0008131B8 (pt) | 1999-02-12 | 2021-05-25 | Daiichi Sankyo Co Ltd | composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno |
| NZ514348A (en) | 1999-05-04 | 2004-05-28 | Exiqon As | L-ribo-LNA analogues |
| US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| DK1569661T3 (da) | 2002-11-18 | 2010-01-11 | Santaris Pharma As | Antisense design |
| JP4716517B2 (ja) * | 2003-06-09 | 2011-07-06 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 神経変性疾患を治療する方法 |
| EP1931778A2 (en) * | 2005-09-15 | 2008-06-18 | Santaris Pharma A/S | RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-Bl00 EXPRESSION |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| DK1984381T3 (da) | 2006-01-27 | 2010-11-01 | Isis Pharmaceuticals Inc | 6-modificerede bicycliske nukleinsyreanaloger |
| WO2007143315A2 (en) | 2006-05-05 | 2007-12-13 | Isis Pharmaceutical, Inc. | Compounds and methods for modulating expression of pcsk9 |
| US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
| CA2651453C (en) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| WO2008113832A2 (en) | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA |
| US8278425B2 (en) | 2007-05-30 | 2012-10-02 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| DK2173760T4 (en) | 2007-06-08 | 2016-02-08 | Isis Pharmaceuticals Inc | Carbocyclic bicyclic nukleinsyreanaloge |
| US8278283B2 (en) | 2007-07-05 | 2012-10-02 | Isis Pharmaceuticals, Inc. | 6-disubstituted or unsaturated bicyclic nucleic acid analogs |
| US8546556B2 (en) | 2007-11-21 | 2013-10-01 | Isis Pharmaceuticals, Inc | Carbocyclic alpha-L-bicyclic nucleic acid analogs |
| DK2285819T3 (da) | 2008-04-04 | 2013-12-02 | Isis Pharmaceuticals Inc | Oligomere forbindelser omfattende neutralt bundne, terminale bicykliske nukleosider |
| US8501805B2 (en) | 2008-09-24 | 2013-08-06 | Isis Pharmaceuticals, Inc. | Substituted alpha-L-bicyclic nucleosides |
| EP2462153B1 (en) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
| EP2490699A1 (en) | 2009-10-20 | 2012-08-29 | Santaris Pharma A/S | Oral delivery of therapeutically effective lna oligonucleotides |
| US8846637B2 (en) | 2010-06-08 | 2014-09-30 | Isis Pharmaceuticals, Inc. | Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
| WO2012027713A2 (en) * | 2010-08-26 | 2012-03-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of snca |
| WO2012068405A2 (en) * | 2010-11-17 | 2012-05-24 | Isis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
| WO2013033230A1 (en) | 2011-08-29 | 2013-03-07 | Isis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| SG11201401314PA (en) | 2011-09-07 | 2014-09-26 | Marina Biotech Inc | Synthesis and uses of nucleic acid compounds with conformationally restricted monomers |
| US9221864B2 (en) | 2012-04-09 | 2015-12-29 | Isis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
| KR102112892B1 (ko) | 2012-11-15 | 2020-05-19 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | 올리고뉴클레오티드 콘쥬게이트 |
| JP6995478B2 (ja) | 2013-05-01 | 2022-01-14 | アイオーニス ファーマシューティカルズ， インコーポレーテッド | Ｈｂｖおよびｔｔｒ発現を調節するための組成物および方法 |
| ES2770667T3 (es) | 2013-06-27 | 2020-07-02 | Roche Innovation Ct Copenhagen As | Oligómeros antisentido y conjugados que se dirigen a PCSK9 |
| EP3220921A1 (en) * | 2014-11-19 | 2017-09-27 | Roche Innovation Center Copenhagen A/S | Lna chiral phosphorothioates |
| US10799523B2 (en) * | 2015-02-04 | 2020-10-13 | F. Hoffmann-La Roche Ag | Tau antisense oligomers and uses thereof |
| US20180023081A1 (en) * | 2015-02-04 | 2018-01-25 | Bristol-Myers Squibb Company | Lna oligonucleotides with alternating flanks |
| TWI794662B (zh) * | 2016-03-14 | 2023-03-01 | 瑞士商赫孚孟拉羅股份公司 | 用於降低pd-l1表現之寡核苷酸 |
| WO2019140231A1 (en) * | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
-
2019
- 2019-01-11 CA CA3087966A patent/CA3087966A1/en active Pending
- 2019-01-11 JP JP2020538629A patent/JP2021510511A/ja active Pending
- 2019-01-11 KR KR1020207023162A patent/KR20200140240A/ko unknown
- 2019-01-11 SG SG11202006528XA patent/SG11202006528XA/en unknown
- 2019-01-11 BR BR112020014011-2A patent/BR112020014011A2/pt unknown
- 2019-01-11 US US16/961,578 patent/US20200362347A1/en active Pending
- 2019-01-11 EA EA202091693A patent/EA202091693A1/ru unknown
- 2019-01-11 EP EP19702766.7A patent/EP3737761A1/en active Pending
- 2019-01-11 AU AU2019208011A patent/AU2019208011A1/en active Pending
- 2019-01-11 CN CN201980018033.XA patent/CN111819283A/zh active Pending
- 2019-01-11 WO PCT/US2019/013255 patent/WO2019140236A1/en unknown
- 2019-01-11 PE PE2020000954A patent/PE20211749A1/es unknown
- 2019-01-11 MX MX2020007439A patent/MX2020007439A/es unknown
-
2020
- 2020-07-07 IL IL275903A patent/IL275903A/en unknown
- 2020-08-05 CO CONC2020/0009715A patent/CO2020009715A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100750788B1 (ko) | ｅＩＦ4Ｅ 발현의 조정 | |
| EP2742135B1 (en) | Linkage modified gapped oligomeric compounds and uses thereof | |
| EP3137476B1 (en) | Linkage modified oligomeric compounds | |
| JP4579911B2 (ja) | スルビビン発現の調節 | |
| JP2024056842A5 (ru) | ||
| JP2016530882A5 (ru) | ||
| JPH09510714A (ja) | オリゴヌクレオチドｎ３’→ｐ５’ホスホルアミデート：合成および化合物；ハイブリダイゼーションおよびヌクレアーゼ耐性特性 | |
| KR20080065617A (ko) | 글루코코티코이드 수용체 발현의 조절 | |
| JP2002539846A (ja) | インターロイキン−５シグナルトランスダクションのアンチセンスモジュレーション | |
| JP2024056820A (ja) | Ｓｃｎ９ａ発現を調節するためのオリゴヌクレオチド | |
| EP4206213A1 (en) | Compounds and methods for modulation of smn2 | |
| JP2014050389A (ja) | マイクロ−ｒｎａおよびその前駆体にハイブリダイズしうる核酸を用いるエリスロポエチンの増加 | |
| JPWO2019140236A5 (ru) | ||
| AU2018421460B2 (en) | Therapeutic uses and methods | |
| WO2008011473A2 (en) | Compositions and their uses directed to hbxip | |
| CN113330118A (zh) | 靶向card9的反义寡核苷酸 | |
| JPWO2019140231A5 (ru) | ||
| ZA200602273B (en) | Modulation of elF4E expression | |
| MXPA05013065A (en) | Modulation of survivin expression |